TCTC Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

TCTC Holdings’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-202	Closed	-$156K	–	492
2025 Q4	$156K	Hold	202	–	–	﹤0.01%	239
2025 Q3	$114K	Hold	202	–	–	﹤0.01%	250
2025 Q2	$106K	Hold	202	–	–	﹤0.01%	257
2025 Q1	$128K	Hold	202	–	–	﹤0.01%	235
2024 Q4	$144K	Hold	202	–	–	0.01%	227
2024 Q3	$212K	Hold	202	–	–	0.01%	198
2024 Q2	$212K	Hold	202	–	–	0.01%	195
2024 Q1	$194K	Hold	202	–	–	0.01%	190
2023 Q4	$177K	Hold	202	–	–	0.01%	197
2023 Q3	$166K	Hold	202	–	–	0.01%	193
2023 Q2	$145K	Hold	202	–	–	0.01%	203
2023 Q1	$166K	Hold	202	–	–	0.01%	201
2022 Q4	$146K	Hold	202	–	–	0.01%	200
2022 Q3	$139K	Hold	202	–	–	0.01%	197
2022 Q2	$119K	Hold	202	–	–	0.01%	211
2022 Q1	$141K	Hold	202	–	–	0.01%	212
2021 Q4	$128K	Sell	202 -20	-9%	-$12.3K	0.01%	240
2021 Q3	$134K	Hold	222	–	–	0.01%	220
2021 Q2	$124K	Hold	222	–	–	0.01%	211
2021 Q1	$105K	Buy	+222	New	+$108K	0.01%	221

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TCTC Holdings's REGN Position: Q1 2026 in Review

TCTC Holdings sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 202 shares — an estimated $156K sold.

TCTC Holdings first reported a position in REGN in Q1 2021 and held it in 20 quarters. The position peaked at $212K in Q3 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

TCTC Holdings reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
TCTC Holdings sold 202 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $156K.
TCTC Holdings first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 20 quarters.
TCTC Holdings's Regeneron Pharmaceuticals position peaked at $212K in Q3 2024.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on TCTC Holdings's 13F filing for Q1 2026, filed 7 May 2026.